ABSTRACT
Background post-injury acquired immunodepression (AID) is frequently assessed by the diminished expression of Human Leukocyte Antigen-D Related on circulating monocytes (mHLA-DR). The relation with mortality and the occurrence of ICU-acquired infections (IAI) requires confirmation in large cohorts of patients. This study tested in a large number of ICU patients from a single center the association of mHLA-DR with mortality and secondary infections.
Methods This prospective, observational study in a surgical ICU of a French tertiary hospital reports mHLA-DR measurements (fixed flow cytometry protocol) done 1st within the 3 days post-admission and 2nd after the 7th day. The other collected parameters were: the SAPS II and SOFA scores, sex, age, comorbidity, mortality and ICU-acquired infections. The associations between mHLA-DR and outcomes were tested by adjusted Fine and Gray sub-distribution competing risk models.
Findings 1053 patients were subdivided into 4 subgroups depending on the main motif for admission. Overall, 151 patients (14.3%) died in the ICU with an independent association with the amplitude of the first mHLA-DR decrease (HR = 0.71 [0.57; 0.95], p < 0.01); 592 patients had a 2nd mHLA-DR measurement of whom 223 patients (37.7%) complicated by IAI. These patients had a lower mHLA-DR than other patients (mHLA-DR = 9.0 log vs. 9.3 log, p < 0.01). IAI occurrence was independently associated with first, the 2nd mHLA-DR level regardless the initial severity (HR = 0.66 [0.51; 0.84], p = 0.001) and second, with the slope between the 1st and 2nd values (HR = 0.62 [0.43; 0.89], p = 0.009).
Interpretation the association between the early mHLA-DR expression and ICU mortality does not improve the prediction given by the severity scores. The persistence or a decrease of low mHLA-DR expression are independent and reliable predictors of ICU-acquired infection.
Funding no financial interest
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author declare they perceived no funding for this research
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The results of these study were presented in part at the 32nd ESICM congress, Berlin September 2019
Data Availability
Data, analytic methods, and study materials are available to other researchers upon motivated request by email
